Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: Results from five national surgical adjuvant breast and bowel project randomized clinical trials

Journal of Clinical Oncology

Volumn 22, Issue 21, 2004, Pages 4247-4254

  Taghian, Alphonse ^a   Jeong, Jong Hyeon ^a   Mamounas, Eleftherios ^a   Anderson, Stewart ^a   Bryant, John ^a   Deutsch, Melvin ^a   Wolmark, Norman ^a  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; MELPHALAN; METHOTREXATE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; MULTIVARIATE ANALYSIS; PNEUMONIA; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TUMOR VOLUME; ADULT; AGED; BREAST TUMOR; LYMPH NODE METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NONPARAMETRIC TEST; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; MELPHALAN; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 12844251947     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.01.042     Document Type: Article

References (30)

1. Early Breast Cancer Trialists' Collaborative Group: Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. Lancet 355:1757-1770, 2000
2. Whelan T, Julian J, Wright J, et al: Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 18:1220-1229, 2000
3. Fisher B, Jeong JH, Anderson S, et al: Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347:567-575, 2002
4. Auquier A, Rutqvist L, Host H, et al: Post-mastectomy megavoltage radiotherapy: The Oslo and Stockholm trials. Eur J Cancer 28:433-437, 1992
5. Ragaz J, Jackson S, Le N, et al: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956-962, 1997
6. Overgaard M, Hansen P, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337:949-955, 1997
7. Overgaard M, Hansen P, Overgaard J, et al: Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized trial. Lancet 353:1641-1648, 1999
8. Adjuvant Therapy for Breast Cancer. NIH Consensus Statement Online November 1-3, 2000; 17:1-23. http://consensus.nih.gov/cons/114/114_statement.htm
9. Recht A, Gray R, Davidson N, et al: Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: Experience of the Eastern Cooperative Oncology Group. J Clin Oncol 17:1689-1700, 1999
10. Katz A, Strom E, Buchholz TA, et al: Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: Implications for postoperative irradiation. J Clin Oncol 18:2817-2827, 2000
11. Wallgren A, Bonetti M, Gelber RD, et al: Risk factors for locoregional recurrence among breast cancer patients: Results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 21:1205-1213, 2003
12. Fisher B, Brown A, Dimitrov N, et al: Two months of doxorubicin- cyclophosphamide with and without interval reinduction therapy compared with 6 months of CMF in positive-node breast cancer patients with tamoxifen- nonresponsive tumors: Results from the NSABP B-15. J Clin Oncol 8:1483-1496, 1990
13. Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005-1018, 1990
14. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997
15. Fisher B, Anderson P, Wickerman D, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from NSABP Project B-22. J Clin Oncol 15:1858-1869, 1997
16. Fisher B, Anderson S, DeCillis A, et al: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from the National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17:3374-3388, 1999
17. Kalbfleisch J, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley and Sons, 1980
18. Gray R: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
19. Cox D: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
20. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
21. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
22. Recht A, Edge S, Solin LJ, et al: Postmastectomy radiotherapy: Guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1539-1569, 2001
23. Ceilley E, Goldberg S, Kachnic L, et al: The radiotherapeutic management of breast cancer: Treatment practice in the United States. Int J Radiat Oncol Biol Phys 51:110, 2001 (abstr)
24. Southwest Oncology Group (SWOG): Randomized trial of post-mastectomy radiotherapy in stage II breast cancer in women with one to three positive axillary nodes, phase III (SWOG 9927). http://swog.org/visitors/ ViewProtocolDetails.asp?ProtocolID=1807
25. Levins M, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 16:2651-2658, 1998
26. Taghian A, Jeong J, Anderson S, et al: Relationship between number of lymph node dissected and the risk of axillary/supraclavicular failure in patients with breast cancer treated by mastectomy and chemotherapy (+/- tamoxifen) without radiation: Results from five NSABP trials. Int J Radiat Oncol Biol Phys 54:89, 2002 (abstr)
27. Lingos T, Recht A, Vicini F, et al: Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 21:355-360, 1991
28. Taghian A, Assaad S, Niemierko A, et al: Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 93:1806-1811, 2001
29. Coen JJ, Taghian AG, Kachnic L, et al: Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys 55:1209-1215, 2003
30. de la Rochefordiere A, Asselain B, Campana F, et al: Age as a prognostic factor in premenopausal breast carcinoma. Lancet 341:1039-1043, 1993